Stock SPRY ARS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 16:57:08 02/05/2024 BST 		5-day change 1st Jan Change
9.145 USD -1.98% Intraday chart for ARS Pharmaceuticals, Inc. +12.61% +66.24%
04-30 ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp CI
04-30 Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand CI

Business Summary

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Number of employees: 25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 96,894,394 70,082,126 ( 72.33 %) 0 72.33 %

Shareholders

NameEquities%Valuation
Deerfield Management Co. LP (Private Equity)
11.48 %
11,077,927 11.48 % 113 M $
RA Capital Management LP
11.25 %
10,860,977 11.25 % 111 M $
Pratik Shah
10.52 %
10,156,204 10.52 % 104 M $
RA Capital Management LP
9.803 %
9,459,678 9.803 % 97 M $
Richard Lowenthal
9.801 %
9,457,753 9.801 % 97 M $
OrbiMed Advisors Private Equity
9.576 %
9,240,887 9.576 % 94 M $
Sarina Tanimoto
5.239 %
5,055,294 5.239 % 52 M $
Robert Bell
4.366 %
4,213,504 4.366 % 43 M $
Fiduciary Trust International LLC
4.247 %
4,098,497 4.247 % 42 M $
SR One Capital Management LP
4.158 %
4,012,903 4.158 % 41 M $

Company contact information

ARS Pharmaceuticals, Inc.

11682 El Camino Real Suite 120

92130, San Diego

+

http://www.ars-pharma.com
address ARS Pharmaceuticals, Inc.(SPRY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for ARS Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.33 USD
Average target price
19 USD
Spread / Average Target
+103.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARS PHARMACEUTICALS, INC. Stock ARS Pharmaceuticals, Inc.
+66.24% 904M
MODERNA, INC. Stock Moderna, Inc.
+18.92% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.08% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.50% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.87% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.21% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.70% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.59% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. Company ARS Pharmaceuticals, Inc.